The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Texas MPN Workshop 2021 | Update on the management of patients with MPNs in transformation
Srdan Verstovsek, MD, The University of Texas, MD Anderson Cancer Center, Houston, TX, talks on the management of patients with myeloproliferative neoplasms (MPNs) in transformation. Dr Verstovsek reports that there are no effective therapies for patients with MPNs in transformation and comments on how improved understanding of the biology of MPN transformation has identified hypomethylating agents, such as azacitidine and decitabine, as potential agents for the treatment of patients with MPNs in transformation. Dr Verstovsek also talks of the benefits of genomic testing. This interview took place at the Texas MPN Workshop: Second Annual Workshop and Meeting in 2021.
